CN108245216A - A kind of aneurysm treatment system - Google Patents
A kind of aneurysm treatment system Download PDFInfo
- Publication number
- CN108245216A CN108245216A CN201611244785.2A CN201611244785A CN108245216A CN 108245216 A CN108245216 A CN 108245216A CN 201611244785 A CN201611244785 A CN 201611244785A CN 108245216 A CN108245216 A CN 108245216A
- Authority
- CN
- China
- Prior art keywords
- aneurysm
- conduit
- treatment system
- hydrogel
- aneurysm treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010002329 Aneurysm Diseases 0.000 title claims abstract description 131
- 238000011282 treatment Methods 0.000 title claims abstract description 68
- 239000000017 hydrogel Substances 0.000 claims abstract description 57
- 239000007924 injection Substances 0.000 claims abstract description 50
- 238000002347 injection Methods 0.000 claims abstract description 50
- 230000003902 lesion Effects 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 11
- 239000008366 buffered solution Substances 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 238000009941 weaving Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000017531 blood circulation Effects 0.000 description 29
- 208000007536 Thrombosis Diseases 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 18
- 201000008450 Intracranial aneurysm Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 208000005189 Embolism Diseases 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000003073 embolic effect Effects 0.000 description 7
- 230000010102 embolization Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000004696 Poly ether ether ketone Substances 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229920002530 polyetherether ketone Polymers 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000007838 tissue remodeling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 2
- 229910001069 Ti alloy Inorganic materials 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009954 braiding Methods 0.000 description 2
- 210000000275 circle of willis Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000025494 Aortic disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 238000012276 Endovascular treatment Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 fluororesin Polymers 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12027—Type of occlusion
- A61B17/12031—Type of occlusion complete occlusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
- A61B17/12118—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm for positioning in conjunction with a stent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Surgical Instruments (AREA)
Abstract
A kind of aneurysm treatment system, including：Conveying device and aquogel system, wherein described conveying device includes injecting conduit for injecting the inside of the aquogel system in lesion site, convey the external delivery conduit of the internal injection conduit and the conducting wire for the delivered inside conduit and the external delivery conduit to be directed to the lesion site；The aquogel system will generate at least two hydrogel generating agents of hydrogel when being included in mixing.Implement the aneurysm treatment system of the present invention, because the effect of endovascular stent is temporary, therefore it can be removed after completion, therefore permanent foreign matter is not had to reside in the aneurysmal sack of patient, therefore side effect and complication can be reduced, in addition, the aneurysm treatment system can also be easily adapted to wide neck and the peculiar aneurysm of shape.
Description
Technical field
The present invention relates to therapeutic field of tumor, more specifically to a kind of aneurysm treatment system.
Background technology
Intracranial aneurysm is a kind of vascular malformation, it means that the expansion of vascular wall and wall construction weaken.Intracranial aneurysm
Often occur in cerebral arterial circle, and cerebral arterial circle is the important component of brain circulation system.Intracranial aneurysm may
There are several fatal complication.If be not treated in time, aneurysm may sustainable growth it is big, cause to have a headache, nausea and other
Symptom.Aneurysm also has the risk of rupture.Aneurysm rupture may cause serious symptom, such as subarachnoid hemorrhage or go out
Courageous and upright apoplexy.These complication have the very high death rate, and need to carry out operative treatment immediately.The risk of aneurysm rupture is every
Year 1.3%, incidence are 10.5 person-times of every 100000 people.
To intracranial aneurysm, there are many therapies, this depends on the state of an illness of patient and aneurysmal state of development.
These treatments include drug supply, and operation folder closes and endovascular technology.Endovascular technology includes intravascular embolic coil art
(endovascular coiling), blood flow are oriented to (flow diversion), bracket for eluting medicament (drug-eluting
Stent) and cutout technology (flow disruption).
Non-cultured microorganism international research meeting (International Study of Unruptured
Intracranial Aneurysms, ISUIA) point out that the risk of rupture is relatively for small aneurysm (being less than 10 millimeters)
It is low, and the death rate performed the operation is quite high.Therefore patient's generally use drug therapy.Drug for hypertension, example can be taken
Such as calcium channel blocker, to control blood pressure, so as to reduce the risk of aneurysm rupture and hinder aneurysmal growth.However, not
The management of ruptured aneurysm is very controversial, mainly since feature and shape are endured in the dissection that Unruptured aneurysm does not have standard
State structure, and the evaluation of risk of the rupture of the Unruptured aneurysm based on medical image is empirical.Medication is in control blood pressure
Aspect is very effective, but its influence to intracranial aneurysm is still unclear.
It is one of earliest method for treating rupture of intracranial aneurysm that operation folder, which closes, is still had in less developed country and area wide
General application.For such treatment, it is required to open cranium, then needs the neck arrangement operation folder across ruptured aneurysm.
Operation folder can close aneurysm from parent blood vessel folder, so as to prevent bleeding.Operation of opening cranium has higher risk, usually exists
During without other feasible patterns, suitable for the symptom of the acute and threat to life after aneurysm rupture.Operation folder closes main scarce
Point is that the death rate of operation of opening cranium is high.Operation folder needs to rest on the body of patient, therefore may result in length as foreign matter
The problem of phase inflammation and immune response.
In order to avoid the high risk of operation of opening cranium, doctor and researcher develop endovascular technology to treat entocranial artery
Knurl only needs to carry out ganglioside GM_3 operation.The basis of neurosurgery is blood vessel imaging and angiography, this just needs to adopt
With catheter in blood vessel and X-ray production apparatus.Surgeon will open a minimally invasive wound in the groin of patient.Conducting wire is stretched into patient
Limb artery in.The conducting wire has radiopaque marker and can be used for passing through blood circulation system.Conducting wire by groin,
Aorta, subclavian artery and vertebral artery, finally to diseased region.By the conducting wire, can be implanted into via conduit implantable medical
Object such as stent.Sometimes foley's tube is used for expandable stent or provides angiopoiesis for angiemphraxis.
Modem devices for the endovascular treatment of intracranial aneurysm are led including endovascular stent, blood vessel interior loop, blood flow
The flow spoiler occurred to device and recently.Stent is widely used in the treatment of angiocardiopathy and abdominal aorta disease.Stent can
So as to it is implanted to above-mentioned position in aforementioned manners.Stent substantially expands the blood vessel of obstruction, and supports blood that is impaired and collapsing
Structural pipe wall.Compared with operation folder closes, embolic coil art greatly reduces the death rate of operation, and complication is not serious.
In the early stage of stent development, they are by bare metal, as stainless steel is made.With the development of alloy technology, by new material
As titanium alloy, cochrome are used to manufacture stent.These materials have excellent performance, including good biocompatibility, shape
Shape remembers and super-elasticity.For bare mental stents, major problem is that leaving foreign matter in the intravascular of patient.The deployment of stent will
The flow field of close region, the blood flow thus upset may result in the formation of patch and blood clot, so as to cause blocking.Bare metal
Another problem of stent is stress concentration, therefore vascular wall can be caused to damage.This is considered as one of restenosis important
Reason.
In order to reduce the side effect of bare metal stent, new technology such as biological absorbable support and medicament elution branch have been developed
Frame.Biodegradable scaffold is by bioabsorbable material, as polylactic acid, polyglycolic acid polymer and its copolymer are formed.
Biodegradable scaffold will support the blood vessel regular hour weakened, and can degrade with the time.Which reduce in the blood vessels
The problem of permanent foreign body.However, the shortcomings that Biodegradable scaffold is compared with bare mental stents, mechanical performance is relatively low.
Due to the property of polymer material, the availability and intensity of these stents are relatively low.Using biodegradable metal, such as the biology of magnesium
Absorbable metal stent is a kind of emerging technology.There is presently no the possible models for finding biological absorbable.
In order to make preferably combine between stent and the liner of blood vessel and reduce blood coagulation risk, it is developed medicine
Object FirebirdTM.The method that drug and stent are provided have it is following several, first, carry the polymerization figure of drug in stent surface coated,
First, construct micro-structure, and embedded drug granule in the hole of micro-structure along stent strut.Vascular endothelial growth factor and
Anti- coagulant medicine is common drug.Bracket for eluting medicament is a kind of up-and-coming technology, but this therapy is suitable
Expensive.Stent manufactures and the complexity of post processing causes the at high price of stent.Simultaneously stent carry drug will with when
Between passage wash away, this will reduce stent the effect of.
Intravascular embolic coil art is widely used in the treatment of intracranial aneurysm, and verified this is a kind of effective
Therapy.Have analysis shows that, compared with neck clipping of performing the operation, the clinical effectiveness of intravascular embolic coil art is more preferable.According to
After above-mentioned ganglioside GM_3 operation deployment conducting wire, the conduit of the medical coil of carrying will be inserted into.The coil is typically by noble metal, such as
Platinum manufacture, be both bio-compatible and under X ray it is visible.After the top of coil enters aneurysm wall, neurosurgeon
It will start from delivery conduit release coil.Under the manipulation of neurosurgeon, coil will be crimped and be filled up in aneurysm
Cavity.The release is usually reversible and the coil can be partly withdrawn so as to preferably be disposed, which may need
Repetition is multiple back and forth, this takes very much.The arrangement of blood vessel interior loop is very delicate, since it is desired that control winding direction and
Bulk density, it is therefore desirable to which process screws up discipline and veteran neurosurgeon.In addition, when the setting of aneurysm top is wired
During circle, blood flow can be reduced in aneurysm, this will cause to form blood clot in aneurysm, and the blood clot in turn will be from parent
Blood vessel embolism aneurysmal sack.This is the reason of therapy of the type is also referred to as embolization processes.Some researchs also found, move
After the occlusion of arteries and veins knurl, neointima layer can be formed in aneurysm neck.The limitation of intravascular embolic coil art is that it can only selected
It is disposed in the case of fixed.For wide neck aneurysm, coil is difficult to be placed in aneurysm, and has the danger being flushed away.The skill
Another problem of art is that platinum line circle is also foreign matter, and will be permanently resident in aneurysm.In addition, its may also trigger it is immune
It reacts and pressure is applied to peripheral nerve and brain tissue.In order to solve these problems, people also begin to consider new technology such as life
Object can absorb coil and elution coil.Stent auxiliary batch be stent and endovascular temporary embolization combination, although increase
The application range of coil, but also improve the cost and difficulty of operation.
In order to treat the aneurysm that volume is larger, shape is extremely peculiar, blood flow guiding technique is described.Blood flow is oriented to utensil
There is supporting structure, but compared with conventional stent, usually with higher elasticity and relatively low porosity.And with traditional stent
Manufacturing technology, such as laser cutting, etching difference, blood flow guider is usually using knitting skill.By a plurality of metal threaded line, example
Such as Ultimum Ti threaded line, it is woven together and is heated to form blood flow guider.Due between metal threaded line
The connection not consolidated, this blood flow guiding will be high flexibility, therefore can preferably be prevented in the position of higher curvature
It controls.The porosity of blood flow guider can easily be increased by adjusting the ratio between the angle of attack and braiding speed.Porous structure will be reduced
Blood flow from parental vessels to aneurysmal sack, this will trigger coagulation cascade.Blood clot will gradually form in aneurysm, and prevent
Only possible bleeding, this is why blood flow guiding technique is also categorized as embolization technique.Blood flow guiding has proved to be blood
The good replacement of pipe interior loop Embolization, but its there is also some problems.Although blood flow guider is high flexibility, its pipe
Shape will generate gap between blood flow guider and blood vessel, therefore occlusion will fail.Meanwhile the length of blood flow guider is led to
Often side branch may be covered more than the size of lesion and blood flow guider.Due to the high porosity of blood flow guider, inflow side
The blood flow of side branch will reduce, this may lead to the ischemia injury of downstream neuronal system.Nearest clinical effectiveness shows
In the long run, blood flow guider led to thrombolysis activity in 14 days, subsequently resulted in delayed crack.With stent and blood vessel interior loop
Embolization is compared, and blood flow guider is not suitable for intracranial aneurysm patients.
A kind of emerging therapy for treating intracranial aneurysm is cutout technology.It is similar with stent and blood flow guider, cutout
Typically lantern shape is fabricated to by biocompatible materials.Cutout can also be implanted by ganglioside GM_3 method.It can incite somebody to action
It is stored in catheter, and is passed through conducting wire and be sent to diseased region.After the top of conduit enters aneurysm wall, release is stopped
Device, cutout, which will expand, to be expanded to be adapted to aneurysm wall.Due to relatively low in cutout bottom porosity, entrance is aneurysmal
Blood flow can interrupt, and embolism occurs.With blood flow be oriented to compared with, cutout method can only allow foreign matter stay in aneurysmal top and cutout only
It can be with aneurysm wall contact.It is formed after blood clot inside the aneurysm, the neointima layer of neck will be developed across, it in this way can be with
Preferably by aneurysm from parental vessels embolism, so as to eliminate the damage to parental vessels wall.Cutout technology can also reduce god
Through surgical operation difficulty, this is compared with intravascular embolic coil art, is easier to arrange.Cutout technology has been demonstrated
It is the treatment for intracranial aneurysm, particularly wide neck and the peculiar aneurysmal very promising technology of shape.However, its
Still there are following technical problem, since foreign solid is resided at the top of aneurysm and may cause inflammatory reaction.Meanwhile it stops
The manufacturing process of the complex geometric shapes of device is complicated, increases the cost of product.
Invention content
The technical problem to be solved in the present invention is, for the drawbacks described above of the prior art, provides a kind of easy to make, treatment
Imitate good, side effect and few intercurrent disease, the aneurysm treatment system for being suitble to various aneurysm illnesss.
The technical solution adopted by the present invention to solve the technical problems is：A kind of aneurysm treatment system is constructed, including：It is defeated
Device and aquogel system are sent, wherein the conveying device includes the inside for injecting the aquogel system in lesion site
Conduit is injected, conveys the external delivery conduit of the internal injection conduit and for by the delivered inside conduit and described
External delivery conduit is directed to the conducting wire of the lesion site；The aquogel system will generate hydrogel when being included in mixing
At least two hydrogel generating agents.
In aneurysm treatment system of the present invention, the internal injection conduit includes injecting in lesion site
Conduit is injected, in the second of lesion site the second hydrogel generating agent of injection in first inside of the first hydrogel generating agent
Conduit is injected in portion, the external delivery conduit be set in the first inside injection conduit, second inside injection conduit and
Outside the conducting wire.
In aneurysm treatment system of the present invention, the conveying device further comprises being arranged on lesion site
The endovascular stent of internal blood vessel.
In aneurysm treatment system of the present invention, the internal injection conduit, the external delivery conduit and institute
The cradle wall for stating conducting wire across the endovascular stent enters the aneurysm cavity of lesion site.
In aneurysm treatment system of the present invention, the endovascular stent be arranged on the internal injection conduit,
The side of the external delivery conduit and the conducting wire, the internal injection conduit, the external delivery conduit and the conducting wire
Enter the aneurysm cavity of lesion site above the side of the endovascular stent.
In aneurysm treatment system of the present invention, the endovascular stent have reticular structure and by braiding or
Person is cut by laser manufacture.
In aneurysm treatment system of the present invention, the endovascular stent can be inhaled for biodegradable or biology
Revenue and expenditure frame is recyclable endovascular stent.
In aneurysm treatment system of the present invention, the internal injection conduit further comprises in lesion position
Point carries out the additional internal injection catheter of functional therapeutic.
In aneurysm treatment system of the present invention, the aquogel system includes liquid polymer solution and chelating
Agent, physiological buffered solution or the thermally sensitive hydrogel solution of hydrogel solution and acidity or alkalinity to pH sensitivities
And hot or cold physiological buffered solution, or combination.
In aneurysm treatment system of the present invention, the liquid polymer solution gather including sodium alginate soln or
Acrylic acid solution, the chelating agent include calcium chloride or calcium gluconate.
Implement the aneurysm treatment system of the present invention, because the effect of endovascular stent is temporary, therefore it can be
It is removed after completing, therefore does not have permanent foreign matter and reside in the aneurysmal sack of patient, therefore side effect can be reduced
And complication, the death rate that these side effects and complication include operation of opening cranium is high, inflammation and immune response and to vascular wall
Damage and reduce blood flow for flowing into side branch etc..In addition, the aneurysm treatment system can also be easily
Wide neck and the peculiar aneurysm of shape are adapted to, and this is exactly that other treatment method is insoluble.Removing stent and hydrogel
After degradation, aneurysm is can be with self-healing.This so that the stress suffered by tissue is smaller and the potential of human body is utilized.Therefore, originally
The aneurysm treatment system of invention can be widely applied to various cases and have the effect of very high.
Description of the drawings
Below in conjunction with accompanying drawings and embodiments, the invention will be further described, in attached drawing：
Figure 1A is the schematic diagram of the conveying device of the aneurysm treatment system of first embodiment according to the present invention；
Figure 1B is the structure diagram of the preferred embodiment of conveying device shown in figure 1A；
Fig. 1 C are the aneurysmal signals of hydrogel embolism of the aneurysm treatment system of first embodiment according to the present invention
Figure；
Fig. 1 D are the formation schematic diagrames of blood clot in aneurysm；
Fig. 2A is the schematic diagram of the conveying device of aneurysm treatment system according to the second embodiment of the present invention；
Fig. 2 B are the formation schematic diagrames of aneurysm embolism；
Fig. 2 C are the formation schematic diagrames of blood clot in aneurysm；
Fig. 2 D-2E show different endovascular stents；
Fig. 3 A are the schematic diagrames of the conveying device of aneurysm treatment system according to the third embodiment of the invention；
Fig. 3 B are the schematic diagrames of the conveying device of aneurysm treatment system according to the fourth embodiment of the invention；
Fig. 3 C are the schematic diagrames of the conveying device of aneurysm treatment system according to the fifth embodiment of the invention；
Fig. 4 A-4D show the various aneurysms that the aneurysm treatment system of the present invention uses.
Specific embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to the accompanying drawings and embodiments, it is right
The present invention is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, and
It is not used in the restriction present invention.
It is based on the analysis of the more than prior art, it can be deduced that draw a conclusion.The principle for the treatment of of intracranial aneurysm is in aneurysm cavity
Interior induction blood clot is formed, so that its embolism from parental vessels.Same principle is suitable for endovascular method, packet
Include intravascular embolic coil art, blood flow is oriented to (flow diversion) and cutout technology.Basic principle is to control using embolism
Treatment scheme is with using blood clot aneurysm embolization.Blood clot carries out tissue remodeling after being formed, and blood clot becomes new blood vessel therebetween
Tissue, and the better aneurysm embolization of new vascular tissue.Nearest zooscopy shows that these tissue remodeling activities may
Including three phases.In early stage, fibrinous reinforcing and degradation occurs.In mid-term stage, macrophages infiltration
To blood clot and hyperplasia is generated, and along with the synthesis of collagen.During the late stages of developmet, the recombination of newly synthesized collagen and flesh into
Fibrocyte is formed.These activities will change aneurysm morphology, and aneurysmal sack will be invisible in angiography.This is theoretical
Also explain the validity of Embolotherapy Methods.
Based on above to the understanding of Embolotherapy Methods, it is proposed that a kind of new treatment system.The system utilizes water in situ
The forming process of gel.Liquid gel forming agent is transmitted to aneurysm cavity to chelate so as to form hydrogel, thus from parent
This angiemphraxis aneurysmal sack.Stagnation environment in aneurysmal sack combines the formation blood clot discharged from the hydrogel newly formed
Compound blood clot will be formed in aneurysm.The hydrogel will continue degradation so that aneurysm is individually by blood clot bolt
Plug.Then, which will carry out tissue remodeling and aneurysm can be with self-healing.Can be added in hydrogel it is additional it is biological because
Son allows them to be discharged in the degradation process of hydrogel, and accelerates aneurysm agglutination.
This treatment system includes two chief components, conveying device and aquogel system.The conveying device packet
It includes and injects conduit for injecting the inside of the aquogel system in lesion site, the outside for conveying the internal injection conduit is defeated
Send conduit and the conducting wire for the delivered inside conduit and the external delivery conduit to be directed to the lesion site.
The external delivery conduit and internal injection conduit can be used for medical grade polymer support, and the conducting wire is by with x-ray mark
The biocompatibility metal of object is made.The aquogel system will generate at least two water-settings of hydrogel when being included in mixing
Glue generating agent.In a preferred embodiment of the invention, the aquogel system includes gel and chelating agent and forms blood
The compound and biotic factor of grumeleuse.In a preferred embodiment of the invention, can also include gel is assisted to convey
The endovascular stent of process.The endovascular stent is generally made of biocompatibility metal or alloy.
The advantages of aneurysm treatment system of the present invention, is, because the effect of endovascular stent is temporary, because
This its can remove after completion, therefore do not have permanent foreign matter and reside in the aneurysmal sack of patient, therefore can be with
Side effect and complication are reduced, the death rate that these side effects and complication include operation of opening cranium is high, inflammation and immune response, with
And blood flow for flowing into side branch etc. is damaged and reduced to vascular wall.In addition, the aneurysm treatment system also may be used
To be easily adapted to wide neck and the peculiar aneurysm of shape, and this is exactly that other treatment method is insoluble.Removing branch
After frame and hydrogel degradation, aneurysm is can be with self-healing.This so that the stress suffered by tissue is smaller and the latent of human body is utilized
Energy.Therefore, the aneurysm treatment system of the invention can be widely applied to various cases and have the effect of very high.
Figure 1A shows the sectional view of the blood vessel 100 with aneurysmal sack 101, is shown according to the present invention first
The conveying device 102 of the aneurysm treatment system of embodiment.Blood flow direction as shown is from left to right.It is shown in Figure 1B defeated
Send the essential structure of device 102.Using two internal injection conduits 105 two kinds of mutual tonics of hydrogel are formed to convey.This two
A internal injection conduit 105 is sleeved in external delivery conduit 103.Conducting wire 104 is defeated for the internal injection conduit and outside
Send the guiding of conduit.The external delivery conduit 103 and the internal injection conduit 105 are made of medical polymer material,
The medical polymer material includes most common polyamide, polyurethane, fluororesin, polyolefin, polyvinyl chloride (PVC), polyamides
Imines and polyether-ether-ketone (Polyether ether ketone, PEEK) can be expanded by physiological saline or buffer solution
Into spherical shape.In one embodiment of the invention, formed hydrogel hydrogel forming agent include liquid polymer solution and
Chelating agent.The liquid polymer solution can be sodium alginate soln, polyacrylic acid solution etc..The chelating agent can be
Calcium chloride, calcium gluconate etc..In another embodiment of the present invention, formed hydrogel hydrogel forming agent include pair
The hydrogel solution of pH sensitivities and the physiological buffered solution of acidity or alkalinity.In another embodiment of the present invention, it is formed
The hydrogel forming agent of hydrogel includes thermally sensitive hydrogel solution and heat or cold physiological buffered solution.Passing through will
Two or the mixing of multigroup hydrogel forming agent, you can to generate hydrogel.
Stainless steel and Ultimum Ti are common conductor materials on the market, usually with radiopaque metal marker
Object combines.Over the course for the treatment of, imaging technique can be used, as conducting wire is directed to lesion by digital subtraction angiography (DSA)
Position.When conducting wire is reached at the top of aneurysm, carrying the external delivery conduit 103 of two internal injection conduits 105 will insert
Enter to lesion site.When two internal injection conduits 105 enter at the top of the aneurysm, two hydrogel forming agents will be gradual
It is discharged into its progress gelatinizing-in-situ at the top of the aneurysm.
Neck aggregation and execution two functions of the hydrogel newly formed at the top of aneurysm.First, it is used as artery
Physical blockage between knurl chamber capsule and parental vessels, so that it can prevent ongoing leakage.Secondly, hydrogel by
It gradually degrades and discharges in biotic factor to aneurysmal sack, so as to which blood clot in intracranial aneurysm be assisted to be formed.For blood clot shape
Into the factor include but not limited to calcium ion, its own is chelating agent, such as：Calcium chloride, calcium gluconate etc..It can also add in
Additional biotic factor includes but not limited to fibroblast, to accelerate following agglutination.Fig. 1 C show 106 bolt of hydrogel
Fill in aneurysm.The formation of blood clot 107 in subsequent intracranial aneurysm is shown in Fig. 1 D.
Fig. 2A shows the sectional view of the blood vessel with aneurysm 200, is shown according to the present invention second and implements
The aneurysm treatment system of example.The aneurysm treatment system includes such as transport system 202, aquogel system and endovascular stent
201。
As previously mentioned, when using the transport system 102 for only including internal injection conduit, external delivery conduit and conducting wire,
There may be following defects.The transport system cannot be limited in the gel formed in aneurysm 200, therefore the hydrogel generated
Aneurysm 200 cannot be completely sealed off.Therefore the factor of the part discharged later for blood clot to be formed will enter parent's blood
Pipe, so as to form blood clot in downstream.If good blood clot, treatment procedure below cannot be formed in aneurysm 200
It will not will likely effectively carry out.Therefore, in order to obtain the effect of more preferable, in presently preferred embodiment of the invention, draw
Endovascular stent technology is entered to solve the problems, such as these.
Endovascular stent 201 can be formed by biocompatible materials including stainless steel, titanium alloy or cobalt chromium.Intravascular branch
The manufacturing method of frame 201 includes but not limited to weave and laser cutting.In surgical procedure, endovascular stent 201 is according to tradition
Endovascular stent merging technology is first placed in below aneurysm neck.In the blood vessels after 201 successful deployment of stent, by conducting wire from
The supra-inguinal same opening of patient is inserted into the vascular system of patient.The conducting wire is visual, and be guided through cradle wall into
Enter aneurysm cavity.When conducting wire is ready to, the internal injection conduit and external delivery conduit that can dispose hydrogel pass through stent
Wall enters aneurysm cavity.By the internal injection conduit, hydrogel forming agent can be injected into aneurysm cavity and dynamic
Hydrogel is formed in arteries and veins knurl chamber.The endovascular stent 201 has reticular structure.Due to the presence of the reticular structure, hydrogel
It will not be leaked into parental vessels from aneurysm cavity.Aneurysm embolism 203 is shown in Fig. 2 B, blood clotting is shown in Fig. 2 C
Block 204 is formed.It then can oneself triggering aneurysm treatment.Fig. 2 D-2E show different endovascular stents 205,206.Institute
Different mesh-densities can just be had by stating endovascular stent 205,206.The selection of stent mesh-density depends on the water newly formed
Gel particle size.The low stent of mesh-density has preferably elasticity, is more easy to be easy to dispose, the low stent of mesh-density then may be used
To be reduced to the risk of the hydrogel of parental vessels leakage.Those skilled in the art can be based on aneurysmal development degree, water
The mesh-density that granular size and other treatment the factor selection of gel are suitble to.
In other embodiments of the invention, the conveying device of aneurysm treatment system of the invention can also use other
Different constructions.As shown in Figure 3A, conveying device 301 can include multiple internal injection conduits, such as in addition to two internal notes
It penetrates except conduit, further includes additional internal injection catheter 302 for various medical applications.Such as it is led by two internal injections
It when pipe injects hydrogel forming agent into aneurysmal sack, finds that aneurysm embolism occurs in surgical procedure, can will add
Internal injection conduit 302 is used as suction.Further, it is also possible to additional internal injection catheter 302 is used for after gelation process
The aneurysmal sack that drug enters embolism is provided.Therefore, the additional internal injection catheter 302 may be used as it is aneurysmal it is any
The functional therapeutic known or worked out later.
In the embodiment shown in figure 3b, the conveying device can include recyclable endovascular stent 303.Due to blood vessel
The function of inner support is temporary blocking parental vessels to prevent any possible hydrogel from leaking, therefore relatively reasonable,
Will not by stent in permanent residents in the blood vessels.In the design, recyclable endovascular stent 303 is first transferred to lesion position
It puts, and part is arranged across aneurysm.Then the internal injection conduit of deployment hydrogel and external delivery conduit.By inside this
Hydrogel forming agent can be injected into aneurysm cavity and hydrogel is formed in aneurysm cavity by injection catheter.In water-setting
After glue fully takes up aneurysm neck, recyclable endovascular stent 303 can be withdrawn.In the present embodiment, the conveying
The recyclable endovascular stent 303 of device is designed to withdraw from the external delivery conduit.The design benefit is to control
After treatment process terminates, foreign matter will not be left in human body.It, can using biology in another alternative embodiment of the present invention
Degradation or biological absorbable support.It is woven for example, by using one or more kinds of biodegradables or bio-absorbable fibers
Stent.
In another embodiment of the invention, endovascular stent can not first be placed.As shown in Figure 3 C, first in aneurysm
It is oriented in chamber and arranges internal injection conduit and external delivery conduit, endovascular stent is then placed on external delivery conduit
Side, then carry out gel-forming process.It designs in this way, in the stage of fetching, since the transmitting path of hydrogel is in blood vessel
Except inner support, therefore when withdrawing endovascular stent, hydrogel will not be destroyed.
In the further embodiment of the present invention, the conveying device can include more or less internal injections
Conduit.In the simplification embodiment of the present invention, the conveying device can include an internal injection conduit and one outer
Portion's delivery conduit.In this embodiment, a kind of hydrogel forming agent can be loaded in the external delivery conduit, and internal injection
Conduit loads another hydrogel forming agent.After the two mixes in aneurysm cavity, hydrogel can be generated.The present invention's
In other preferred embodiments, more internal injection conduits can be selected.For example, in a preferred embodiment of the invention, it can
To include four internal injection conduits, wherein the first internal injection conduit contains sodium alginate soln, the second internal injection conduit
Calcium chloride is contained, third internal injection conduit contains the hydrogel solution to pH sensitivities, and the second internal injection conduit contains alkalinity
Physiological buffered solution.Sodium alginate soln and calcium chloride mixing and/or the hydrogel solution to pH sensitivities with it is described
The physiological buffered solution mixing of alkalinity, will generate hydrogel respectively.
The aneurysm treatment system of the present invention is capable of the aneurysm of particularly effective treatment specific type.Fig. 4 A-4D are shown
The various aneurysms that the aneurysm treatment system of the present invention uses.Gel polymer can be applied to the giant aneurysm of sealing
(Fig. 4 A) and wide neck aneurysm (Fig. 4 B), and due to the natural quality of polymer, in gelation process, it can be spontaneously
It is adapted to aneurysm wall.In addition, according to neurosurgeon, using therapeutic scheme or device is currently available that, there are two types of aneurysms
It is difficult to treat, i.e. furcation aneurysm and netraneurysm.And aneurysm treatment system using the present invention, for bifurcation
Aneurysm, aquogel polymer easily form sealant (Fig. 4 c) in knurl neck.And for netraneurysm, aquogel polymer can
To combine auxiliary stand filling aneurysm cavity (Fig. 4 d).Therefore, aneurysm treatment system using the present invention, can especially effectively
The various specific types for the treatment of aneurysm
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement made within refreshing and principle etc., should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of aneurysm treatment system, which is characterized in that including：Conveying device and aquogel system, wherein the conveying dress
It puts and injects conduit including being used to inject the inside of the aquogel system in lesion site, convey the outer of the internal injection conduit
Portion's delivery conduit and for the delivered inside conduit and the external delivery conduit to be directed to leading for the lesion site
Line；The aquogel system will generate at least two hydrogel generating agents of hydrogel when being included in mixing.
2. aneurysm treatment system according to claim 1, which is characterized in that the internal injection conduit include for
Lesion site injects the first inside injection conduit of the first hydrogel generating agent, is given birth to for injecting the second hydrogel in lesion site
Into the second inside injection conduit of agent, the external delivery conduit is set in injection conduit inside described first, in described second
Portion is injected outside conduit and the conducting wire.
3. aneurysm treatment system according to claim 1 or 2, which is characterized in that the conveying device further comprises
It is arranged on the endovascular stent of the internal blood vessel of lesion site.
4. aneurysm treatment system according to claim 3, which is characterized in that the internal injection conduit, the outside
Delivery conduit and the conducting wire pass through the cradle wall of the endovascular stent to enter the aneurysm cavity of lesion site.
5. aneurysm treatment system according to claim 3, which is characterized in that the endovascular stent is arranged in described
The side of portion's injection conduit, the external delivery conduit and the conducting wire, the internal injection conduit, the external delivery conduit
Enter the aneurysm cavity of lesion site above the side of the endovascular stent with the conducting wire.
6. aneurysm treatment system according to claim 3, which is characterized in that the endovascular stent has reticular structure
And by weaving or being cut by laser manufacture.
7. aneurysm treatment system according to claim 3, which is characterized in that the endovascular stent is biodegradable
Either biological absorbable support or for recyclable endovascular stent.
8. aneurysm treatment system according to claim 2, which is characterized in that the internal injection conduit further comprises
For carrying out the additional internal injection catheter of functional therapeutic in lesion site.
9. aneurysm treatment system according to claim 1, which is characterized in that the aquogel system includes liquid polymerization
Object solution and chelating agent, the physiological buffered solution or temperature sensitive of hydrogel solution and acidity or alkalinity to pH sensitivities
Hydrogel solution and heat or cold physiological buffered solution, or combination.
10. aneurysm treatment system according to claim 9, which is characterized in that the liquid polymer solution includes sea
Solution of sodium alginate is gathered or acrylic acid solution, and the chelating agent includes calcium chloride or calcium gluconate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611244785.2A CN108245216A (en) | 2016-12-29 | 2016-12-29 | A kind of aneurysm treatment system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611244785.2A CN108245216A (en) | 2016-12-29 | 2016-12-29 | A kind of aneurysm treatment system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108245216A true CN108245216A (en) | 2018-07-06 |
Family
ID=62719127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611244785.2A Pending CN108245216A (en) | 2016-12-29 | 2016-12-29 | A kind of aneurysm treatment system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108245216A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110876654A (en) * | 2019-11-12 | 2020-03-13 | 苏州凝智新材料发展有限公司 | Treatment system for vascular lesions and application thereof |
| CN112274206A (en) * | 2020-12-29 | 2021-01-29 | 北京泰杰伟业科技有限公司 | Hydrogel turbulence device and turbulence device conveying system |
| CN112274204A (en) * | 2020-06-12 | 2021-01-29 | 微创神通医疗科技（上海）有限公司 | Medical spring ring |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040215124A1 (en) * | 2003-04-25 | 2004-10-28 | Medtronic Ave, Inc. | Method and apparatus for aneurismal treatment |
| CN1556689A (en) * | 2001-07-20 | 2004-12-22 | ���ŷ� | Aneurysm treatment device |
| CN1893987A (en) * | 2003-12-17 | 2007-01-10 | 密执安州立大学董事会 | Compositions and methods for improved occlusion of vascular defects |
| CN101056595A (en) * | 2004-11-16 | 2007-10-17 | 微温森公司 | Compositions, systems and methods for treatment of defects in blood vessels |
| WO2008074027A1 (en) * | 2006-12-13 | 2008-06-19 | Biomerix Corporation | Aneurysm occlusion devices |
| WO2009064697A2 (en) * | 2007-11-13 | 2009-05-22 | Boston Scientific Scimed, Inc. | Combination coil and liquid embolic for embolization |
| US20110029011A1 (en) * | 2009-08-03 | 2011-02-03 | Ashish Awasthi | Clotting method for the repair of vascular defects and malformations |
| CN103083057A (en) * | 2004-01-22 | 2013-05-08 | 微排放器公司 | Aneurysm treatment device |
| WO2013130937A1 (en) * | 2012-03-01 | 2013-09-06 | Tufts University | Endovascular silk-protein based embolization of blood vessels |
| CN103717153A (en) * | 2011-08-05 | 2014-04-09 | W.L.戈尔及同仁股份有限公司 | Polymer-based occlusion devices, systems and methods |
| CN104168844A (en) * | 2012-01-04 | 2014-11-26 | 急速医疗有限公司 | Devices and methods for assisting medical treatments |
| CN105007842A (en) * | 2012-12-05 | 2015-10-28 | 急速医疗有限公司 | Devices and methods for assisting medical treatments |
| CN105209075A (en) * | 2013-04-18 | 2015-12-30 | 香港科技大学 | Biocompatible in situ hydrogel |
| CN204971706U (en) * | 2015-09-11 | 2016-01-20 | 高不郎 | A local close support of netting for aneurysm |
| CN105833413A (en) * | 2016-03-04 | 2016-08-10 | 上海沐春投资管理有限公司 | Novel peripheral vessel intervention exchange sheath |
| EP3092958A1 (en) * | 2015-05-11 | 2016-11-16 | Cook Medical Technologies LLC | Medical assembly and device |
-
2016
- 2016-12-29 CN CN201611244785.2A patent/CN108245216A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1556689A (en) * | 2001-07-20 | 2004-12-22 | ���ŷ� | Aneurysm treatment device |
| US20040215124A1 (en) * | 2003-04-25 | 2004-10-28 | Medtronic Ave, Inc. | Method and apparatus for aneurismal treatment |
| US20100063472A1 (en) * | 2003-12-17 | 2010-03-11 | Becker Timothy A | Compositions and methods for improved occlusion of vascular defects |
| CN1893987A (en) * | 2003-12-17 | 2007-01-10 | 密执安州立大学董事会 | Compositions and methods for improved occlusion of vascular defects |
| CN103083057A (en) * | 2004-01-22 | 2013-05-08 | 微排放器公司 | Aneurysm treatment device |
| CN101056595A (en) * | 2004-11-16 | 2007-10-17 | 微温森公司 | Compositions, systems and methods for treatment of defects in blood vessels |
| WO2008074027A1 (en) * | 2006-12-13 | 2008-06-19 | Biomerix Corporation | Aneurysm occlusion devices |
| WO2009064697A2 (en) * | 2007-11-13 | 2009-05-22 | Boston Scientific Scimed, Inc. | Combination coil and liquid embolic for embolization |
| US20110029011A1 (en) * | 2009-08-03 | 2011-02-03 | Ashish Awasthi | Clotting method for the repair of vascular defects and malformations |
| CN103717153A (en) * | 2011-08-05 | 2014-04-09 | W.L.戈尔及同仁股份有限公司 | Polymer-based occlusion devices, systems and methods |
| CN104168844A (en) * | 2012-01-04 | 2014-11-26 | 急速医疗有限公司 | Devices and methods for assisting medical treatments |
| WO2013130937A1 (en) * | 2012-03-01 | 2013-09-06 | Tufts University | Endovascular silk-protein based embolization of blood vessels |
| CN105007842A (en) * | 2012-12-05 | 2015-10-28 | 急速医疗有限公司 | Devices and methods for assisting medical treatments |
| CN105209075A (en) * | 2013-04-18 | 2015-12-30 | 香港科技大学 | Biocompatible in situ hydrogel |
| EP3092958A1 (en) * | 2015-05-11 | 2016-11-16 | Cook Medical Technologies LLC | Medical assembly and device |
| CN204971706U (en) * | 2015-09-11 | 2016-01-20 | 高不郎 | A local close support of netting for aneurysm |
| CN105833413A (en) * | 2016-03-04 | 2016-08-10 | 上海沐春投资管理有限公司 | Novel peripheral vessel intervention exchange sheath |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110876654A (en) * | 2019-11-12 | 2020-03-13 | 苏州凝智新材料发展有限公司 | Treatment system for vascular lesions and application thereof |
| CN112274204A (en) * | 2020-06-12 | 2021-01-29 | 微创神通医疗科技（上海）有限公司 | Medical spring ring |
| CN112274206A (en) * | 2020-12-29 | 2021-01-29 | 北京泰杰伟业科技有限公司 | Hydrogel turbulence device and turbulence device conveying system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100455325C (en) | Compositions and methods for improved occlusion of vascular defects | |
| CN106456183B (en) | Locking device | |
| US20080228259A1 (en) | Endovascular devices and methods to protect aneurysmal wall | |
| CN102302377B (en) | Mesh tubular spring for embolism and preparation method thereof | |
| Girdhar et al. | Thrombogenicity assessment of Pipeline, Pipeline Shield, Derivo and P64 flow diverters in an in vitro pulsatile flow human blood loop model | |
| CN106068107B (en) | Embolization device, for the instrument and its method at embolism target vessel position | |
| JP2012520297A (en) | Products and methods for the treatment of vascular diseases | |
| US10695462B2 (en) | On-demand degradable medical devices | |
| JP2007307409A (en) | Aneurysm treatment device | |
| WO2013056497A1 (en) | Intravascular implant device kit and preparation method for implant device | |
| CN108245216A (en) | A kind of aneurysm treatment system | |
| CN205885483U (en) | A support that is used for originated portion of shutoff artery branch aneurysm | |
| CN108888391A (en) | A kind of non-crossing bracket of monofilament | |
| CN106859723B (en) | In-vivo degradable spring ring for intravascular interventional medicine | |
| CN208048758U (en) | A kind of recyclable blood flow guider | |
| EP3367926B1 (en) | Aneurysm occluder | |
| KR101585028B1 (en) | Polymer coated stent for treatment of aneurysm and manufacturing method of the same | |
| CN211750297U (en) | Treatment system for vascular lesions | |
| CN208989271U (en) | A kind of degradable local dense net bracket | |
| CN202146320U (en) | Mesh tubular embolism spring | |
| Orfaniotis et al. | Technical considerations to avoid microvascular complications during groin lymph node free flap transfer | |
| CN208851723U (en) | The dedicated auxiliary stand of aneurysm liquid embolizing agent | |
| Sherman et al. | Investigation of new flow modifying endovascular image-guided interventional (EIGI) techniques in patient-specific aneurysm phantoms (PSAPs) using optical imaging | |
| CN110876654A (en) | Treatment system for vascular lesions and application thereof | |
| WO2014036809A1 (en) | Endoluminal drug delivery devices with applications in blood vessels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20210312 |